LeMaitre Vascular
LMAT Mid CapHealthcare · Medical Instruments & Supplies
Mis à jour: Aug 2, 2026, 22:14 UTC
Price Chart
Indicateurs clés
Valuation Analysis
About the Company
LeMaitre Vascular en bref
LeMaitre Vascular (LMAT) is currently trading at 87,97 € with a market capitalization of 2,0 Md €. The trailing P/E ratio stands at 37.25x, with a forward P/E of 31.12x. The 52-week range spans from 68,94 € to 102,47 €; the current price is 14.1% below the yearly high. Year-over-year revenue growth stands at +11.2%. The net profit margin stands at 24.35%.
💰 Dividende
LeMaitre Vascular pays an annual dividend of 0,87 € per share, representing a yield of 0.99%. The payout ratio stands at 31.25%.
📊 Avis des analystes
8 analystes évaluent LeMaitre Vascular (LMAT) au consensus : Acheter. L'objectif de cours moyen est de 103,11 €, soit un potentiel de +17.2% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 88,56 € à 117,22 €.
LeMaitre Vascular : la thèse d'investissement en détail
LeMaitre Vascular (LMAT) operates in the Healthcare — specifically Medical Instruments & Supplies — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
Le scénario haussier
Revenue is growing at a healthy 11.2% pace year-over-year, suggesting the business model continues to find new customers and pricing power. Earnings growth of 41.7% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. With a gross margin near 71.33%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns.
Le scénario baissier
Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.
Valorisation en contexte
The EV/EBITDA multiple of 27.15x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.
À surveiller
- The forward P/E of 31.12x is meaningfully below the trailing 37.25x — analysts expect earnings to step up; the next earnings release is the test.
Thèse d'investissement : forces et faiblesses
- Rentable avec une marge nette de 24.35%
- Rentabilité élevée des capitaux propres (16.55% ROE)
- Marge brute élevée de 71.33% — signe d'un pouvoir de fixation des prix
- Consensus des analystes : Buy
- Bilan solide avec faible endettement (D/E 46.68)
- Free cash flow positif
- –Actuellement jugée surévaluée
Aperçu technique
Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).
Profil de risque
The data points to relatively defensive market behavior, elevated short interest (8.14%).
Trading Data
💵 Dividend Info
Related Stocks in the Same Sector
More Santé stocks
Top peers in the same sector — ranked by market cap.
Where can I buy LeMaitre Vascular?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
📊 Plutôt un fonds qu’une action isolée ? Comparatif d’ETF :
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news